<DOC>
	<DOC>NCT01061710</DOC>
	<brief_summary>The purpose of this study is to collect the efficacy and safety information in subjects who have been retreated with varenicline (Champix®) within 52 weeks of initial treatment for their appropriate use in daily practice and are participants for varenicline Drug Use Investigation protocol A3051109 ((NCT# NCT00772941).</brief_summary>
	<brief_title>Varenicline (Champix®) Special Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>The subjects have been retreated with varenicline within 52 weeks, and subjects have been enrolled to varenicline Drug Use Investigation protocol A3051109.</detailed_description>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Male or Female subjects intend to quit tobacco use who are prescribed varenicline (Champix®) by their Physicians Subjects who are prescribed varenicline (Champix®) for the second time within 52 weeks of initial treatment. Nonparticipants of varenicline (Champix®) Drug use Investigation protocol A3051109.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Smoking</keyword>
	<keyword>smoking cessation</keyword>
	<keyword>Japanese</keyword>
	<keyword>varenicline</keyword>
	<keyword>retreatment</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>